Optimizing PAH Care Delivery for Better Outcomes

Author(s):

Marius Hoeper, MD

Following a review of strategies and care delivery models that could help optimize the management of PAH, Marius Hoeper, MD, discusses his recent publication on the long-term impact of sotatercept on morbidity and mortality.

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

Now Viewing

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

From a clinical perspective, what strategies or care delivery models could help optimize the management of pulmonary arterial hypertension (PAH) and potentially reduce the overall burden on the health care system while improving patient outcomes?
Discuss your recent publication on using a population health model to predict the long-term impact of the new PAH therapy sotatercept on morbidity and mortality. How can such modeling tools be leveraged by clinicians to better anticipate and plan for the clinical and economic effects of emerging PAH treatments?